rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1-2
|
pubmed:dateCreated |
2008-2-6
|
pubmed:abstractText |
In the present study, we investigated the potential anti-angiogenic mechanism and anti-tumour activity of beta-eudesmol using in vitro and in vivo experimental models. Proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with vascular endothelial growth factor (VEGF, 30 ng/ml) and basic fibroblast growth factor (bFGF, 30 ng/ml) was significantly inhibited by beta-eudesmol (50-100 microM). Beta-eudesmol (100 microM) also blocked the phosphorylation of cAMP response element binding protein (CREB) induced by VEGF (30 ng/ml) in HUVEC. Beta-eudesmol (10-100 microM) inhibited proliferation of HeLa, SGC-7901, and BEL-7402 tumour cells in a time- and dose-dependent manner. Moreover, beta-eudesmol treatment (2.5-5 mg/kg) significantly inhibited growth of H(22) and S(180) mouse tumour in vivo. These results indicated that beta-eudesmol inhibited angiogenesis by suppressing CREB activation in growth factor signalling pathway. This is the first study to demonstrate that beta-eudesmol is an inhibitor of tumour growth.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1028-6020
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
159-67
|
pubmed:dateRevised |
2009-7-21
|
pubmed:meshHeading |
pubmed-meshheading:18253884-Animals,
pubmed-meshheading:18253884-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18253884-Cell Line, Tumor,
pubmed-meshheading:18253884-Cell Proliferation,
pubmed-meshheading:18253884-Cyclic AMP Response Element-Binding Protein,
pubmed-meshheading:18253884-Dose-Response Relationship, Drug,
pubmed-meshheading:18253884-Endothelial Cells,
pubmed-meshheading:18253884-Fibroblast Growth Factor 2,
pubmed-meshheading:18253884-Humans,
pubmed-meshheading:18253884-Male,
pubmed-meshheading:18253884-Mice,
pubmed-meshheading:18253884-Molecular Structure,
pubmed-meshheading:18253884-Neoplasms,
pubmed-meshheading:18253884-Neovascularization, Pathologic,
pubmed-meshheading:18253884-Phosphorylation,
pubmed-meshheading:18253884-Phytotherapy,
pubmed-meshheading:18253884-Sesquiterpenes, Eudesmane,
pubmed-meshheading:18253884-Time Factors,
pubmed-meshheading:18253884-Vascular Endothelial Growth Factor A
|
pubmed:articleTitle |
Beta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation.
|
pubmed:affiliation |
Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China. maenlong@hotmail.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|